OC.09.3 INFLIXIMAB DOSE-REDUCTION IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS IN PROLONGED DEEP REMISSION: POTENTIAL IMPLICATIONS ON DE-ESCALATION STRATEGIES IN A REAL LIFE CLINICAL SETTING WITHOUT A THERAPEUTIC DRUG MONITORING (TDM) APPROACH

Saved in:
Bibliographic Details
Published inDigestive and liver disease Vol. 51; p. e101
Main Authors Buda, A., Facchin, S., Lorenzon, G., Barberio, B., Zingone, F., Savarino, E., D'Incà, R.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 25.03.2019
Online AccessGet full text

Cover

More Information
ISSN:1590-8658
1878-3562
DOI:10.1016/S1590-8658(19)30185-9